


DOCKET NO.: 216457US0CONT



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF:

Masafumi TAKIGUCHI, et al.

SERIAL NO.: 09/994,617

FILED: NOVEMBER 28, 2001

:

: GROUP ART UNIT: 1654

:

: EXAMINER: TELLER

FOR: HIV-SPECIFIC CTL INDUCING PEPTIDES AND MEDICAMENTS FOR
PREVENTING OR TREATING AIDS COMPRISING THE PEPTIDES

#10
HQS
7/25/03
RECEIVED
JUL 15 2003
TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

In response to the Official Action dated June 13, 2003, Applicants elect, with traverse,
Group XI, Claim 2 (drawn to a DNA molecule coding for the peptide, the peptides
comprising SEQ ID NO: 4), for further prosecution.

REMARKS

The Office has required restriction in the present application as follows:

- | | |
|------------------|---|
| Groups I-VII: | Claims 1 and 3, drawn to a peptide, the peptides comprising SEQ ID NO: 1-7 (wherein Group I corresponds to SEQ ID NO:1, Group II corresponds to SEQ ID NO:2, etc.); |
| Groups VIII-XIV: | Claim 2, drawn to a DNA molecule coding for the peptide, the peptides comprising SEQ ID NO: 1-7 (wherein Group VIII corresponds to SEQ ID NO:1, Group IX corresponds to SEQ ID NO:2, etc.). |

Applicants elect, with traverse, Group XI, Claim 2 (drawn to a DNA molecule coding
for the peptide, the peptides comprising SEQ ID NO: 4), for further prosecution.